Product information and disease descriptionProduct descriptionProduct informationDosing and administration
Administration
3 evidence topics · 3 sources
Subcutaneous administration with potential self-administration at home
Intravenous infusion over 60 minutes in the phase 1b study
“Phase 1b double‐blind placebo‐controlled trial (NCT04538794) in adults with moderate‐to‐severe (urticaria activity score over 7 days [UAS7] ≥ 16) antihistamine–refractory CSU treated with intravenous barzolvolimab for 12 weeks with a 12‐week follow‐up” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients were randomly assigned in a 4:1 ratio to receive a 60‐min intravenous infusion of either barzolvolimab or placebo (saline) Q4W or Q8W according to their assigned cohort” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote